Serum Exosomal SF3B4 Marker for Early HCC Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for hepatocellular carcinoma lack reliable noninvasive biomarkers for early detection and treatment response, with existing markers like alpha-fetoprotein showing low sensitivity, necessitating the development of a new serum biomarker for improved diagnostic accuracy.
Innovation Solution
A serum exosomal SF3B4 marker composition is developed, allowing for the measurement of SF3B4 expression levels in blood-derived serum exosomes, which serves as a diagnostic biomarker for hepatocellular carcinoma, enabling noninvasive in vitro diagnosis and potential treatment through expression or activity inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional markers like alpha-fetoprotein are used for hepatocellular carcinoma diagnosis, then the diagnostic process is simple and widely available, but the sensitivity is only about 60% and insufficient for early detection
Solution Approach 1:
The patent extracts and isolates exosomes from serum samples, then specifically identifies and measures SF3B4 protein within these exosomes. This extraction approach allows detection of cancer-specific markers at very low concentrations, achieving high sensitivity (85.7% in early stage HCC) while using standardized laboratory techniques that are not excessively complex
Solution Approach 2:
The patent uses exosomes as intermediary carriers that transport SF3B4 protein from cancer cells into the bloodstream. By detecting SF3B4 within these exosomal structures rather than free in serum, the method achieves enhanced sensitivity for early detection while maintaining a relatively simple immunodetection workflow
2Reliability
If biopsy is performed to obtain genetic information for hepatocellular carcinoma diagnosis, then accurate genetic information can be obtained, but there is a high risk of bleeding due to underlying cirrhosis
Solution Approach 1:
The patent detects SF3B4 protein expression in serum exosomes, which serves as a molecular copy or surrogate marker of the cancer genome. This copying approach provides reliable diagnostic information about hepatocellular carcinoma without requiring physical tissue sampling, thereby eliminating bleeding risks associated with biopsy in cirrhotic patients
3Reliability
If multiple blood draws are performed during treatment to predict treatment response, then treatment efficacy can be monitored, but this increases the frequency of invasive procedures
Solution Approach 1:
The patent utilizes serum exosomes that naturally circulate in the bloodstream and can be obtained through routine blood draws. The SF3B4 marker within these exosomes provides treatment response information without requiring additional invasive procedures, making the monitoring process as simple as regular blood work that patients already undergo
Data Source
AI summary
The present disclosure relates to a serum exosomal SF3B4 marker composition for diagnosing early stage hepatocellular carcinoma for noninvasive in vitro diagnosis, wherein, by analyzing an expression level of SF3B4 in plasma proteins as well as expression of SF3B4 in exosomes present in sera of hepatocellular carcinoma patients, the possibility as the most suitable liquid biopsy marker was identified, and a new noninvasive biomarker with high diagnostic accuracy in early stage hepatocellular carcinoma for which no reliable biomarker exists at this present was discovered. As such, by using exosomes to identify cancer cell genomes and proteomes without biopsy, the exosomes are highly applicable in the future as a diagnostic biomarker that is useful in a disease group with a high risk in the biopsy such as hepatocellular carcinoma.